SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1).BP102 is a humanized recombinant monoclonal IgG1 antibody.
The primary objective of this study is to investigate the safety and efficacy of the subjects who given the combination therapy.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2282196 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA